Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years

Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children

Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.